Amneal Pharmaceuticals Inc (AMRX):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Amneal Pharmaceuticals Inc (AMRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C7992)・商品コード:DATA904C7992
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:48
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Amneal Pharmaceuticals Inc (Amneal) formerly Amneal Pharmaceuticals LLC, is an integrated specialty pharmaceutical company that produces generic, specialty and biosimilar medicines. Its product portfolio includes generic and specialty drugs in the therapeutic areas of analgesic, antibiotic, antiepileptic, antihypertensive, anti-inflammatory, cough suppressant, vitamin supplement, cholinergic agonist, immunosuppressant and urinary antiseptic, among others. The company offers products in various dosage forms such as oral solids and liquids, injectables, topicals, creams and ointments, transdermals, inhalation, ophthalmic and otic liquids and other device driven products. Amneal also offers services which include product research and development, active pharmaceutical ingredient (API) manufacturing, packaging, distribution and account management. The company has operational facilities across the US, India and Ireland as well as commercial offices in Switzerland, Germany, the UK, Australia, Spain, Germany, Switzerland and Scandinavia. Amneal is headquartered in Bridgewater, New Jersey, the US.

Amneal Pharmaceuticals Inc (AMRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Amneal Pharma Acquires Generic Business of Actavis Australia 13
Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 14
Partnerships 16
Amneal Pharma Enters into Licensing Agreement with mAbxience 16
Merger 17
Amneal Merges with Impax 17
Licensing Agreements 19
Amneal Pharma Enters into Licensing Agreement with Jerome Stevens Pharma 19
Amneal Pharma Enters into Licensing Agreement with Adello Biologics 20
Amneal Pharma Enters into Development and Licensing Agreement with Iconovo 21
Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 22
Equity Offering 23
Amneal Pharma Plans to Raise Funds through Public Offering of Shares 23
Amneal Pharma to Raise USD854 Million in Private Placement of Shares 24
Debt Offering 25
Amneal Pharma Raises USD600 Million in Private Placement of 2% Notes Due 2022 25
Asset Transactions 26
ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 26
ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 28
Acquisition 29
Aristo Pharma Acquires Amneal Nordic and Amneal Pharma Spain 29
Novartis May Acquire Amneal Pharma 30
Amneal Pharma Plans to Acquire Epsilon Pharma for up to USD16.9 Million 31
Amneal Pharmaceuticals Inc – Key Competitors 32
Amneal Pharmaceuticals Inc – Key Employees 33
Amneal Pharmaceuticals Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 36
Financial Announcements 36
Aug 09, 2018: Amneal Announces Solid Second Quarter 2018 Financial Results 36
Mar 02, 2018: Amneal 4th Quarter Full Year 2017 Quarterly Financial Report 39
Corporate Communications 42
Feb 06, 2018: Andrew S. Boyer Joins Amneal Pharmaceuticals as Executive Vice President, Commercial Operations 42
Dec 18, 2017: Robert Stewart to Join Amneal Pharma as President 43
Dec 18, 2017: Robert Stewart to Join Amneal Pharmaceuticals as President 44
Clinical Trials 45
Apr 21, 2017: Impax to Present Data on Investigational Drug IPX203 at the 2017 American Academy of Neurology Annual Meeting 45
Other Significant Developments 46
May 11, 2018: Amneal Announces Actions to Streamline Operations and Capture Cost Synergies 46
Jan 23, 2018: PSEG Long Island Presents Amneal Facility with Energy-Efficiency Rebates 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amneal Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Amneal Pharma Acquires Generic Business of Actavis Australia 13
Amneal Pharma Acquires Four Generic Products from Actavis for USD10 Million 14
Amneal Pharma Enters into Licensing Agreement with mAbxience 16
Amneal Merges with Impax 17
Amneal Pharma Enters into Licensing Agreement with Jerome Stevens Pharma 19
Amneal Pharma Enters into Licensing Agreement with Adello Biologics 20
Amneal Pharma Enters into Development and Licensing Agreement with Iconovo 21
Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 22
Amneal Pharma Plans to Raise Funds through Public Offering of Shares 23
Amneal Pharma to Raise USD854 Million in Private Placement of Shares 24
Amneal Pharma Raises USD600 Million in Private Placement of 2% Notes Due 2022 25
ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 26
ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 28
Aristo Pharma Acquires Amneal Nordic and Amneal Pharma Spain 29
Novartis May Acquire Amneal Pharma 30
Amneal Pharma Plans to Acquire Epsilon Pharma for up to USD16.9 Million 31
Amneal Pharmaceuticals Inc, Key Competitors 32
Amneal Pharmaceuticals Inc, Key Employees 33
Amneal Pharmaceuticals Inc, Other Locations 34
Amneal Pharmaceuticals Inc, Subsidiaries 34

List of Figures
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amneal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Amneal Pharmaceuticals Inc (AMRX):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C7992)販売に関する免責事項を必ずご確認ください。
★調査レポート[Amneal Pharmaceuticals Inc (AMRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆